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Abstract
MUC1 is a large, transmembrane mucin glycoprotein expressed at the apical surface of a variety of
reproductive tract epithelia. Functions attributed to MUC1 include those generally associated with
mucins such as lubrication and hydration of cell surfaces as well as protection from microorganisms
and degradative enzymes. In addition, MUC1 is an effective inhibitor of both cell-cell and cell-
extracellular matrix interactions in both normal and malignant contexts. Moreover, a series of
recent studies has shown that the highly conserved cytoplasmic tail of MUC1 interacts specifically
with a series of important signal transducing molecules including β-catenin, Grb2 and erbB family
members. MUC1 expression in normal epithelia can be quite dynamic, varying in response to
steroid hormone or cytokine influences. Following malignant transformation, MUC1 often
becomes highly overexpressed, loses its apical restriction, and displays aberrant glycosylation and
altered mRNA splice variants. Regulation of MUC1 expression can occur at the transcriptional
level. In addition, post-translational regulation of cell surface expression occurs via the activity of
cell surface proteases or "sheddases" that release soluble forms of the large ectodomains. This
review will briefly summarize studies of MUC1 expression and function in reproductive tissues with
particular emphasis on the uterus. In addition, current knowledge of the mechanisms of MUC1
gene regulation, metabolic processing and potential signal transducing functions will be presented.
MUC1 structure and expression
The MUC1 gene encodes a type-I transmembrane glyco-
protein that is expressed on the apical surface of most sim-
ple epithelia, including mammary gland, female
reproductive tract, lung, kidney, stomach, gall bladder,
and pancreas as well as some non-epithelial cell types
[reviewed in [1]]. The human MUC1 gene spans 4 to 7 kb
and is comprised of 7 exons that can be alternatively
spliced to form transcripts from 3.7 to 6.4 kb. The full-
length protein contains three domains: short cytoplasmic
and transmembrane domains that are highly conserved
among species, and a large extracellular domain (Fig. 1).
The extracellular domain in humans contains 20–125 tan-
dem repeats of 20 amino acids enriched in serine, threo-
nine, and proline residues. Due to these features, the
tandem repeat domain has the potential for extensive O-
glycosylation. The core protein has an estimated weight of
120–225 kDa, though the mature glycosylated form
ranges from 250–500 kDa [reviewed in [1,2]]. The proline
residues and glycosylation give rise to a rigid, extended
structure that protrudes 200–500 nm above the cell sur-
face, much farther than the distance spanned by most cell-
surface proteins, including syndecans and integrins (fig.
2). In addition, in most simple epithelia, including those
of the uterus, mucins not only are abundant, but also are
concentrated at the apical surface. Collectively, these
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observations are consistent with mucins functioning as a
protective barrier with adhesion-modulating properties.
While probably the best studied, MUC1 is just one exam-
ple of a class of molecules collectively referred to as
mucins. Mucins may be grouped as transmembrane or
soluble (see Table 1). As noted above for MUC1, many of
these mucins are physically very large molecules with
extended structures due to the abundance of proline resi-
dues and high degree of glycosylation (see Fig. 2). None-
theless, some are of comparable size to other cell surface
proteins, e.g., MUC13 [3]. MUC1 and MUC4 have many
similar features and proposed functions. Other recently
described transmembrane mucins such as MUC16 and
MUC17 also may share properties with MUC1 and
MUC4, but not enough information is available to suggest
their physiological function. This review will focus on
studies of MUC1 as a prototype of large, transmembrane
mucins in the context of uterine biology. As noted in
Table 1, expression of many of the known mucins has not
yet been examined in uterine tissues; only MUC1 and
MUC4 have been carefully examined through the men-
strual cycle and during early pregnancy.
MUC1 Functions
Mucins have numerous functions in the glycocalyx. Their
high degree of glycosylation provides lubrication, pre-
vents dehydration, and offers protection from proteolysis.
Microbial challenge is frequent in most mucous mem-
branes, and mucins protect against attack by sterically
inhibiting microbial access to the cell surface. Bacterial
adhesins bind mucin carbohydrates at the cell surface
[4,5], a process that normally protects against infection. In
addition, extended transmembrane mucins, such as
MUC1 and MUC4, modulate cell-cell and cell-extracellu-
lar matrix (ECM) interactions by steric hindrance
Protein structure and normal expression pattern of MUC1 Figure 1
Protein structure and normal expression pattern of MUC1. Schematic diagram of the size and structure of the full-
length MUC1 protein relative to the plasma membrane. The horizontal bar indicates the distance that most cell surface pro-
teins extend into the pericellular space. The three major domains of MUC1 are indicated to the left: (1) an N-terminal, extra-
cellular domain (ECTO); (2) a single, membrane spanning domain (TM); and (3) a C-terminal cytoplasmic domain (CT). A list of 
epithelial and non-epithelial human tissues that normally express MUC1 is indicated to the right.
Epithelial tissues that normally
express MUC1
• mammary gland
• female reproductive tract
(except ovary)
• prostate
•t e s t i s
• salivary gland
• digestive tract (except large intestine and colon)
• pancreas
• liver (bile ducts)
• lung
• kidney (distal tubules and collecting ducts)
• bladder
•e y e
Non-epithelial cells that 
express MUC1:
• hematopoietic cells 
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[reviewed in [1,2]]. In fact, overexpression of MUC1 in
tumor cells is suggested to promote metastasis through
disruption of these interactions [6,7]. This activity is
directly related to the number of tandem repeats in the
Model of mucins and other cell surface glycoproteins/proteoglycans Figure 2
Model of mucins and other cell surface glycoproteins/proteoglycans. The figure schematically portrays structures of 
four size classes of mucins as well as consensus structures for syndecans and integrins. All extracellular portions of these mol-
ecules are roughly drawn to scale. Blue squiggles represent O-linked oligosaccharides while red squiggles represent gly-
cosaminoglycans. Integrins, syndecans and most other all surface receptors do not extend beyond 50 nm from the cell surface; 
however, with the exception of MUC13, mucins extend much farther due to the extende3d structures contributed by the pra-
line-rich heavily O-glycosylated tandem repeat domains. MUC1 and MUC4 are the largest transmembrane mucins, extending 
>200 nm from the cell surface. The ectodomain structures of MUC16 and MUC17 are considerably shorter than those of 
MUC1 and MUC4, but still much larger than other surface glycoproteins. Soluble mucins, such as MUC2, 5AC, 5B and 19 are 
even larger, reading 500–100 nm in length.
Table 1: Mucin Expression in the Uterus
MUCIN TYPE UTERINE EXPRESSION REFERENCE
Soluble or Gel-forming









MUC1 Yes See text
MUC3 No Gipson et al., 1997 [69]
MUC4 Yes See text
MUC10-18 UnknownReproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/4
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ectodomains of MUC1 and MUC4 since reduction of
these motifs alone makes these molecules ineffective
inhibitors of cell-cell and cell-ECM interactions [8,9].
In addition to mechanical functions, the MUC1 cytoplas-
mic tail has been shown to associate with β-catenin [10],
as well as with other signaling molecules, e.g., Grb2/Sos
[11], suggesting a potential role for MUC1 in cell signal-
ing [reviewed in [12]]. In the mammary gland, MUC1
expression increases markedly during lactation along with
increased MUC1:erbB1 interactions [13]. Tyrosine phos-
phorylation of the MUC1 cytoplasmic tail occurs in both
intact MUC1 and chimeric molecules consisting of CD8
ectodomains and the MUC1 cytoplasmic tail [14,15]. It is
not clear if MUC1 phosphorylation or interactions with
signal transducing proteins change in response to physio-
logical stimuli. Activation of erbB1 with EGF induces tyro-
sine phosphorylation of the MUC1 cytoplasmic tail
[13,16] and activation of ERK 1/2 [13]. Moreover, EGF
mediated activation of ERK 1/2 is drastically enhanced in
the presence of high levels of MUC1 in the mouse mam-
mary gland [13]. Thus, potential stimuli, including
growth factors or cytokines directly or through activation
of their receptors may affect MUC1 stability, localization
at the cell surface, or phosphorylation state. Direct inter-
actions with the MUC1 ectodomain, e.g., by microbes or
selectins, also could conceivably trigger signaling events.
In this regard, increased tyrosine phosphorylation of the
MUC1 cytoplasmic tail is associated with cell-substratum
adhesion [14]. Thus, MUC1, and perhaps other mucins,
have the potential to function as receptors either alone or
in cooperation with known signal transducing proteins.
Studies in tumor cells indicate that the amount and type
of MUC1 expressed modulate immune responses to these
cells. MUC1 is differentially glycosylated in many cancer-
ous cells, exposing tumor-specific epitopes that may trig-
ger an immune response [17,18]; however, MUC1 also
has been shown to protect cancer cells from immune cell
attack [19,20], indicating both immunostimulatory and
immunosuppressive functions for MUC1. MUC1 and
other mucins are abundantly expressed at the apical sur-
face of luminal and glandular uterine epithelia [21-24].
Muc1 (mouse nomenclature) null mice exhibit chronic
infection and inflammation of the uterus as a result of
increased infection by normal bacteria of the reproductive
tract [25]. In vitro studies have shown that cells expressing
a high level of MUC1 at the cell surface are refractory to
blastocyst attachment, while removing MUC1 from the
cell surface allows attachment [25,26]. Taken together,
these studies suggest that MUC1 plays a role in protecting
the endometrium from microbial attack, but must be lost
in order for embryo implantation to occur. Indeed, Muc1
expression in mice is lost throughout the uterine epithelia
by day 4 of pregnancy when the uterus is receptive to blas-
tocyst attachment [22,27]. In contrast, rabbits display gen-
erally high Muc1 expression during the receptive phase
although local loss of Muc1 is observed at implantation
sites [23]. Similarly, MUC1 expression in humans is max-
imal during the implantation phase [21]. In vitro studies
indicate that human blastocysts produce factors that lead
to local MUC1 loss on monolayers of human uterine epi-
thelia [28]. In contrast, recent studies indicate that human
blastocysts display selectins on their cell surface and that
complementary selectin ligands are found on the uterine
surface during the receptive phase [29]. Uterine epithelial
MUC1 carries selectin ligands throughout the cycle ([30],
J. Julian, S. Fisher and D.D. Carson, unpublished observa-
tions); however, it is not clear if selectin ligands are found
on most, or a minor subset of, MUC1 molecules. None-
theless, it must be considered that MUC1 participates in
selectin-dependent interactions in the uterus and, thus,
may promote cell-cell interactions in some contexts.
Regulation of MUC1 expression
Appropriate tissue-specific expression and regulation of
MUC1 was demonstrated in a MUC1 transgenic mouse
created using 1.6 kb of 5' and 2.3 kb of 3' flanking
sequence [31]. In vitro deletion analysis of the 1.6 kb prox-
imal promoter region demonstrated that elements in the
region from 400 bp to 600 bp upstream of the transcrip-
tional start site are required for maximal promoter activ-
ity, and elements between -150 bp and -60 bp are required
for tissue specificity [32,33]. Several of the regulatory ele-
ments in the MUC1 5' flanking sequence have been func-
tionally characterized (Fig. 3). The E box (E-MUC1) at -
84/-72 is required for transcriptional repression in cells
that do not normally express MUC1 [33]. The transcrip-
tion factor Snail has been shown to bind this region to
repress MUC1 transcription [34]. Two Sp1 sites (GC
boxes) have been shown to be important for transcrip-
tional activation in epithelial cells and repression in non-
epithelial cells [33,35,36]. The Sp1 site at -99/-90 is
required for cErbB2/Ras-mediated transcriptional repres-
sion [37], and this element overlaps the binding site of
SpA, a transcriptional repressor that competes with Sp1
for binding [35]. A region from -531 to -517 was shown
to be required for MUC1 transcriptional activation in
human colon cancer cells in response to treatment with
normal colon conditioned medium [38]. The interferon
(IFN)-γ-mediated up-regulation of MUC1 expression in
human mammary epithelial cells was shown to act
through signal transducer and activator of transcription
(STAT)-1α binding to the STAT binding site at -503/-495
[39,40]. STAT3 is able to bind the STAT binding element
in human mammary epithelial cells in response to inter-
leukin (IL)-6 treatment [40]. The κB binding element at -
589/-580 in the MUC1 promoter region is required for
up-regulation of MUC1 expression in response to TNF-α
treatment, and TNF-α and IFN-γ can synergize toReproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/4
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stimulate MUC1 expression in human mammary epithe-
lial cells [39].
Similar to its actions on MUC1 gene expression, TNFα,
acting through NFκB activation, greatly stimulates MUC2
and MUC5AC gene activation in human lung epithelial
cell lines [41-44]. This activation proceeds via a Src-
dependent, Ras-MEK1/2/ERK1/2-pp90srk pathway.
MUC4 expression also is cytokine regulated, but in a dif-
ferent, intriguing fashion. TGFβ1 strongly inhibits MUC4
expression at the post-translational level of mucin
processing [45]. Recent studies indicate that the TGFβ1
response is repressed by IFN-γ, an activator of the expres-
sion of other mucin genes. This response involves inter-
play between SMADs and STAT1 that appear to control
activity of the MUC4 processing step [46]. It is not clear if
the TGFβ1/SMAD system similarly regulates the expres-
sion of other mucins.
MUC1 expression is controlled by steroid hormones in
the mammary gland and uterus [22,28,47]. Several puta-
tive progeterone and estrogen response elements have
been identified in the human MUC1 promoter by
sequence analysis [48,49]. In both mice and humans, pro-
gesterone levels are maximal, relative to estrogen, at the
implantation phase, but changes in MUC1 expression in
response to steroid hormones is different in the two spe-
cies. In mice, uterine Muc1 expression is greatly stimu-
lated by estrogen. While progesterone alone has no effect,
it strongly antagonizes estrogen-stimulated Muc1 expres-
sion [22,27]. Experiments with antiestrogens and antipro-
gestins indicate that the actons of both hormones are
mediated by nuclear receptors [22]. Nonetheless, direct
regulation of the Muc1 promoter by ER-α or -β, or PR-A or
-B, has not been demonstrable [50]. Conversely, endome-
trial MUC1 expression in humans is higher during the
secretory phase, a progesterone-dominated portion of the
cycle [21,28]. The reason for these differences in hormo-
nal responsiveness among species is not clear. Possibilities
include species-specific differences in cis  promoter ele-
ments and transcription factor/transcriptional coregulator
contexts. Further studies are necessary to understand the
molecular basis of steroid hormone regulation of MUC1
gene expression.
The MUC1 proximal promoter Figure 3
The MUC1 proximal promoter. The 1.4 kb human MUC1 proximal promoter is sufficient for driving proper tissue-specific 
expression in a transgenic mouse model. Cis elements that have been shown to be important for MUC1 regulation include the 
two Sp1 sites, the κB site, a STAT binding element, and E-MUC1 (E box). The location of several potential progesterone 
response elements (PRE) also are shown.
(-346, -190, -62)Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/4
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MUC1 Metabolism and Shedding
In mouse uterine epithelial cells, Muc1 is translated, glyc-
osylated and moves to the cell surface with a median
transit time of 142 min [51]. During this process, it is pro-
teolytically cleaved at a site between the transmembrane
and tandem repeat domains. In spite of this, the het-
erodimer remains tightly associated in an SDS-labile, but
otherwise stable, interaction [52-54]. After arrival at the
cell surface, MUC1 may undergo several fates. One is
recycling through the trans aspect of the Golgi apparatus
([55], a process that would lead to no net loss; however,
Muc1's metabolic half life ranges from 12–16 hr ([51] and
refs. within) demonstrating that mechanisms exist to
degrade even these extremely biochemically resistant mol-
ecules. A second fate is endocytosis followed by degrada-
tion in an intracellular acidic compartment, presumably
lysosomes [51]. The balance of Muc1 turnover probably is
due to cell surface release or shedding (see below). Shed-
ding results in separation of the cytoplasmic tail from the
ectodomain in all cases studied, implicating a proteolytic
event [51,54,56]; however, recent studies indicate that
mutation of the site of intracellular metabolic cleavage
inhibits MUC1 shedding, indicating that cleavage at this
site is critical for subsequent cell surface release [57].
Soluble, presumably shed, MUC1 fragments are found in
bodily fluids [58,59] as well as uterine flushings from
women during the receptive phase of the cycle [60].
Women who suffer recurrent spontaneous miscarriages
have reduced levels of MUC1 in uterine flushings, suggest-
ing that a defect in the MUC1 release system underlies
some human fertility defects [60,61]. These observations
suggest that MUC1 proteolytic release occurs in vivo as
well. Alternative mRNA splicing generates a secreted form
of MUC1, MUC1/SEC, lacking the transmembrane and
cytoplasmic tail [62]. Transcripts for MUC1/SEC are
detectable in human endometrium indicating that at least
a portion of the soluble MUC1 found in uterine flushings
is contributed by MUC1/SEC, rather than shedding [63].
Although the intracellular cleavage site 65 amino acids
upstream of the MUC1 transmembrane domain has been
identified, the protease mediating the metabolic cleavage
has not [53]. As noted above, this site appears to be critical
for MUC1 shedding, at least in certain cellular contexts
[57]. Nonetheless, these results do not preclude an addi-
tional cleavage occurring at a later stage of processing.
Thus, due to its extreme resistance to externally added pro-
teases [64], it is unlikely that cell surface MUC1 release is
mediated by the actions of an external protease [52,64].
Various serine, cysteine and aspartic acid protease inhibi-
tors do not inhibit Muc1 ecotodomain release [51], impli-
cating the involvement of other protease classes. Others
have suggested that release is catalyzed post-translation-
ally by an endogenous proteolytic activity [56,65].
Muc1 expression is elevated during the peri-implantation
period in rabbits [23]; however, careful examination of
implantation sites in vivo and in vitro reveals that Muc1 is
lost solely at the site of embryo-uterine apposition [23].
Interestingly, elevated expression of the cell surface pro-
tease, ADAM 9, accompanies Muc1 loss at implantation
sites in rabbits [66], implicating ADAM 9 in the implanta-
tion process in this species. Uterine MUC1 also appears to
be elevated during the receptive phase in humans [21].
Although implantation sites have not been studied in
humans, in vitro implantation models indicate that MUC1
is lost at the site of embryo attachment in humans as well
[26,28], suggesting that factors expressed on the blastocyst
surface or released with limited diffusibility trigger MUC1
loss in rabbits and humans. These findings are consistent
with an induced loss of MUC1 at the site of attachment,
perhaps triggered by the blastocyst itself or a factor(s) pro-
duced by the blastocyst and mediated through activation
of a uterine cell surface protease. Taken together, these
observations led to the hypothesis that an endogenous
protease(s) mediates constitutive and induced MUC1
release from the human uterine epithelial cell surface.
Examination of MUC1 shedding in the human uterine
epithelial cell line, HES, demonstrated that this process
was unaffected by a variety of synthetic and naturally
occurring protease inhibitors; however, a subset of syn-
thetic and one endogenous metalloprotease inhibitor
blocked constitutive as well as phorbol ester-stimulated
MUC1 shedding [67], implicating an ADAM (a disin-
tegrin and metalloprotease) as a MUC1 sheddase. PCR
profiling identified a subset of catalytically active ADAMs
including tumor necrosis-α converting enzyme (TACE)/
ADAM17 present in HES cells as well as the receptive
phase human endometrium. Cotransfection of MUC1
into wild-type as well as TACE/ADAM17-deficient mouse
embryonic fibroblasts revealed that constitutive and phor-
bol ester-stimulated shedding was abolished in TACE/
ADAM17-deficient cells. Furthermore, TACE/ADAM17
was identified in both lumenal and glandular epithelium
in the receptive phase human endometrium implicating a
role for this protease in MUC1 shedding in vivo. No infor-
mation is yet available on whether endometrial TACE/
ADAM17 expression or activation is modulated during
the cycle in any species. Additional studies indicate that
pervanadate-stimulated MUC1 shedding occurred even in
TACE/ADAM17-deficient cells, demonstrating that addi-
tional sheddases are operative under certain circum-
stances (A. Thathiah and D.D. Carson, manuscript
submitted). Thus, it is possible that multiple proteases
contribute to MUC1 shedding. Alterations in the expres-
sion of activation of these enzymes may contribute to
acute, localized MUC1 removal.Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/4
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Conclusion
In many respects, MUC1 is a prototypical large, trans-
membrane mucin. In the uterus these glycoproteins are
almost completely restricted to the uterine epithelium
where they lubricate and maintain hydration of the cell
surface as well as present major barriers to microbes and
implanting blastocysts. In the latter case, it is critical that
this barrier be removed to create embryonic access to the
uterine epithelium. In many species, this appears to be
accomplished by down-regulation of MUC1 gene expres-
sion. In this regard, progress has been made in under-
standing transcriptional regulation of MUC1 as well as
other mucin genes. Nonetheless, more work needs to be
done to understand the mechanisms underlying steroid
hormone regulation of these genes. In other cases, MUC1
expression and function appears to be modulated by
shedding. TACE/ADAM17 and MT1-MMP represent two
enzymes likely to mediate MUC1 shedding in uterine epi-
thelia. While MUC1 shedding provides a dynamic and
rapid way of modulating cell surface MUC1 expression
and function, many questions remain. In order to create
blastocyst access to the epithelial surface, it is predicted
that a large fraction of the apically-disposed MUC1 must
be lost; however, so far we have found no individual fac-
tors that reduce the cellular complement of MUC1 by
more than 5–10% (A. Thathiah, M. Brayman, N. Dharma-
raj and D.D. Carson, unpublished observations). The
receptive phase endometrial milieu is complex and influ-
enced by factors of both maternal and embryonic origin.
It is possible that a combination of factors synergize,
potentially activating multiple sheddases, to clear MUC1
from the apical cell surface. Adressing this possibility will
require careful examination of candidate factors alone
and in combination. Sheddases also require activation to
be functional and assays need to be developed to deter-
mine whether proteins not only are present, but also
active during the transition to the receptive state. Since
sheddases are likely to play important roles in regulating
bioavailability of other important epithelial cell surface
components, e.g., HB-EGF [68], developing a thorough
understanding of the enzymes operative in the
endometrium is likely to impact other aspects of our
understanding of uterine physiology. Finally, the roles of
mucins in uterine signal transduction are only starting to
be appreciated. How mucins activate or function in intra-
cellular signaling cascades and what factors modulate
mucin participation in these events should be carefully
studied in physiologically relevant contexts.
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